Research Article
The Prognostic Value of Decreased KLF4 in Digestive System Cancers: A Meta-Analysis from 17 Studies
Table 1
Baseline characteristics of the seventeen included studies.
| | Author | Year | Region | Type | Stage | Number of patients | Follow-up (months) | Assay | Negative (n) | Cut off | Outcome | HR estimation | HR (95% CI) | NOS score |
| | Chen | 2012 | China | CRC | I–IV | 99 | NA | IHC | 34 | Low expression | OS | SC | 2.62 (1.88–7.18) | 6 | | IHC | 34 | Low expression | MFS | SC | 2.88 (1.09–26.54) | | | Xu | 2008 | China | CRC | I–IV | 60 | NA | IHC | 42 | Negative expression | OS | SC | 1.81 (0.91–2.77) | 6 | | Tang | 2014 | China | CRC | I–IV | 85 | NA | RT-PCR | 42 | Low expression | OS | SC | 2.08 (1.54–5.26) | 7 | | Patel | 2010 | USA | CRC | I–IV | 365 | NA | IHC | 249 | <10% staining | OS | SC | 1.08 (1.03–1.47) | 7 | | IHC | 249 | <10% staining | DFS | SC | 1.75 (1.06–2.86) | | | Lee | 2014 | South Korea | CRC | I–IV | 125 | 0.4–96.3 | RT-PCR | 80 | <2150 copies/μl | OS | SC | 0.61 (0.44–1.35) | 8 | | Hsu | 2013 | China | GC | I–IV | 118 | NA | IHC | 31 | Low expression | OS | SC | 1.71 (1.03–2.85) | 8 | | Li | 2012 | China | GC | I–IV | 264 | 9–69 | IHC | 150 | IRS ≤ 1 | OS | Reported | 2.89 (1.18–9.23) | 8 | | IHC | 150 | IRS ≤ 1 | DFS | Reported | 2.14 (1.03–4.37) | | | Wei | 2005 | USA | GC | I–IV | 39 | NA | IHC | 27 | IRS ≤ 3 | OS | SC | 2.10 (1.14–3.87) | 7 | | Sun | 2017 | China | HCC | I–III | 148 | NA | IHC | 67 | IRS ≤ 3 | OS | Reported | 2.91 (1.50–5.66) | 8 | | IHC | 67 | IRS ≤ 3 | RFS | Reported | 2.60 (1.45–4.68) | | | Hsu | 2014 | China | HCC | I–IV | 205 | 2.4–147.6 | IHC | 160 | Staining intensity ≤ 1+ | DSS | SC | 2.51 (1.18–5.16) | 8 | | Sun | 2016 | China | HCC | I–III | 98 | NA | IHC | 29 | Negative expression | OS | Reported | 4.59 (1.59–13.34) | 8 | | IHC | 29 | Negative expression | RFS | Reported | 5.42 (2.42–12.06) | | | Yin | 2013 | China | HCC | I–III | 57 | 5–58 | RT-PCR | 50 | Low expression | OS | SC | 0.11 (0.02–0.52) | 8 | | RT-PCR | 50 | Low expression | RFS | SC | 0.25 (0.09–0.77) | | | Shimada | 2012 | Japan | ESCC | I–IV | 80 | 40 | IHC | 50 | IRS ≤ 3 | DSS | SC | 1.34 (0.73–2.47) | 8 | | Ma | 2014 | China | ESCC | I–III | 98 | 3–72 | IHC | 55 | IRS ≤ 3 | OS | SC | 1.35 (0.72–2.53) | 8 | | Sun | 2015 | China | ESCC | I–IV | 149 | NA | IHC | 95 | IRS ≤ 4 | OS | SC | 0.65 (0.41–1.03) | 7 | | Yang | 2016 | China | PDAC | I–IV | 106 | 24 | IHC | 59 | <25% staining | OS | SC | 2.76 (1.68–4.52) | 8 | | Funel | 2011 | Italy | PDAC | NA | 22 | 11.6–55.2 | IHC | 16 | Negative expression | OS | Reported | 2.50 (1.00–6.30) | 7 | | IHC | 16 | Negative expression | DFS | Reported | 2.60 (1.00–6.50) | |
|
|
CRC: colorectal cancer; GC: gastric cancer; HCC: hepatocellular carcinoma; ESCC: esophageal squamous cell carcinoma; PDAC: pancreatic ductal adenocarcinoma; IHC: immunohistochemistry; RT-PCR: reverse transcription polymerase chain reaction; IRS: immunoreaction score; OS: overall survival; DFS: disease-free survival; DSS: disease-specific survival; MFS: metastasis-free survival; DSS: disease-specific survival; RFS: recurrence-free survival; SC: survival curve; NA: not available; 95% CI: 95% confidence interval; HR: hazard ratio; NOS: Newcastle-Ottawa scale.
|
